This review highlights the genetic and molecular mechanisms underlying congenital heart valve diseases, providing insights into potential therapeutic implications.
No takes yet. Share an insight, caveat, or question.
No immediate changes to clinical management of congenital valve disease; leaves open translation of molecular pathways to targeted therapies.
Lincoln et al. (2011) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: